Results 111 to 120 of about 15,930 (153)

Cyclin-dependent kinase 4 and 6 inhibitors and the breast cancer immune ecosystem: immune remodeling, resistance, and therapeutic reprogramming. [PDF]

Front Immunol
Tang Y, Zhu Y, Liu S, Han X, Zhang H, Zhao W.   +5 more
europepmc   +1 more source

Post-CDK4/6 inhibitor therapy in HR+/HER2- advanced breast cancer: expanding options and persisting uncertainties. [PDF]

Explor Target Antitumor Ther
Hollinger AM, Bill R.
europepmc   +1 more source

MKRN2-Mediated Degradation of IGF2BP3 Suppresses MYC and Enhances CDK4/6 Inhibitor Sensitivity in Bladder Cancer. [PDF]

Cancers (Basel)
Pan Q, Shi Q, Zhao Y, Yu T, Bai S, Zhu H, Zhang W, Li Y, Liu Z, Li H, Wang Z, Tong Z.   +11 more
europepmc   +1 more source

Age, Age-Related Comorbidities and Survival in Palbociclib, Ribociclib and Abemaciclib Users With Advanced Breast Cancer: A Nation-Wide Retrospective Cohort Study. [PDF]

Pharmacoepidemiol Drug Saf
Rajamaki B, Tenhunen O, Pylkkänen L, Vo T, Paakinaho A, Turpeinen M, Hartikainen S, Tolppanen AM.   +7 more
europepmc   +1 more source

Targeting PFKFB3 to enhance CDK4/6 inhibitor response in ER+ breast cancer. [PDF]

Breast Cancer Res
Telang S, Clem BF, Miret AAH, Price L, Dougherty SM, Schmitz A, Yin X, Ma X, Zhang X, Chesney J, Imbert-Fernandez Y.   +10 more
europepmc   +1 more source

Correction to 'The kinase inhibitor palbociclib binds to HIV TAR RNA with very low nanomolar affinity and exquisite specificity'. [PDF]

Nucleic Acids Res
europepmc   +1 more source